Sign In
Buy NGVT
Ingevity Earnings Calls
| Release date | Nov 05, 2025 |
| EPS estimate | $0.785 |
| EPS actual | $1.31 |
| EPS Surprise | 66.88% |
| Revenue estimate | 270.933M |
| Revenue actual | 333.1M |
| Revenue Surprise | 22.95% |
| Release date | Aug 04, 2025 |
| EPS estimate | $1.02 |
| EPS actual | $1.39 |
| EPS Surprise | 36.27% |
| Revenue estimate | 372M |
| Revenue actual | 365.1M |
| Revenue Surprise | -1.85% |
| Release date | May 05, 2025 |
| EPS estimate | $0.740 |
| EPS actual | $0.99 |
| EPS Surprise | 33.78% |
| Revenue estimate | 285.467M |
| Revenue actual | 284M |
| Revenue Surprise | -0.514% |
| Release date | Feb 18, 2025 |
| EPS estimate | $0.290 |
| EPS actual | $0.95 |
| EPS Surprise | 227.59% |
| Revenue estimate | 328.2M |
| Revenue actual | 298.8M |
| Revenue Surprise | -8.96% |
Last 4 Quarters for Ingevity
Below you can see how NGVT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 18, 2025 |
| Price on release | $45.84 |
| EPS estimate | $0.290 |
| EPS actual | $0.95 |
| EPS surprise | 227.59% |
| Date | Price |
|---|---|
| Feb 11, 2025 | $45.50 |
| Feb 12, 2025 | $44.62 |
| Feb 13, 2025 | $45.18 |
| Feb 14, 2025 | $45.10 |
| Feb 18, 2025 | $45.84 |
| Feb 19, 2025 | $48.26 |
| Feb 20, 2025 | $46.74 |
| Feb 21, 2025 | $46.01 |
| Feb 24, 2025 | $46.11 |
| 4 days before | 0.747% |
| 4 days after | 0.589% |
| On release day | 5.28% |
| Change in period | 1.34% |
| Release date | May 05, 2025 |
| Price on release | $35.52 |
| EPS estimate | $0.740 |
| EPS actual | $0.99 |
| EPS surprise | 33.78% |
| Date | Price |
|---|---|
| Apr 29, 2025 | $33.03 |
| Apr 30, 2025 | $32.98 |
| May 01, 2025 | $33.28 |
| May 02, 2025 | $35.04 |
| May 05, 2025 | $35.52 |
| May 06, 2025 | $39.20 |
| May 07, 2025 | $39.23 |
| May 08, 2025 | $40.29 |
| May 09, 2025 | $40.47 |
| 4 days before | 7.54% |
| 4 days after | 13.94% |
| On release day | 10.36% |
| Change in period | 22.52% |
| Release date | Aug 04, 2025 |
| Price on release | $40.85 |
| EPS estimate | $1.02 |
| EPS actual | $1.39 |
| EPS surprise | 36.27% |
| Date | Price |
|---|---|
| Jul 29, 2025 | $44.09 |
| Jul 30, 2025 | $42.35 |
| Jul 31, 2025 | $41.79 |
| Aug 01, 2025 | $40.40 |
| Aug 04, 2025 | $40.85 |
| Aug 05, 2025 | $49.56 |
| Aug 06, 2025 | $48.89 |
| Aug 07, 2025 | $50.51 |
| Aug 08, 2025 | $51.27 |
| 4 days before | -7.35% |
| 4 days after | 25.51% |
| On release day | 21.32% |
| Change in period | 16.28% |
| Release date | Nov 05, 2025 |
| Price on release | $54.46 |
| EPS estimate | $0.785 |
| EPS actual | $1.31 |
| EPS surprise | 66.88% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $53.51 |
| Oct 31, 2025 | $53.72 |
| Nov 03, 2025 | $53.84 |
| Nov 04, 2025 | $52.58 |
| Nov 05, 2025 | $54.46 |
| Nov 06, 2025 | $46.20 |
| Nov 07, 2025 | $48.40 |
| Nov 10, 2025 | $49.86 |
| Nov 11, 2025 | $49.53 |
| 4 days before | 1.78% |
| 4 days after | -9.05% |
| On release day | -15.17% |
| Change in period | -7.44% |
Ingevity Earnings Call Transcript Summary of Q3 2025
Ingevity reported a strong operational quarter (Q3 2025) with total sales of $362M and continued margin expansion — adjusted EBITDA margin reached 33.5%, marking the sixth consecutive quarter of year-over-year margin improvement. Management announced the sale of the Industrial Specialties business for $110M (expected to close early 2026) and plans to use most proceeds to reduce debt. Free cash flow was $118M in Q3, enabling $25M of share repurchases and accelerated deleveraging; net leverage finished the quarter at ~2.7x and is expected to be ~2.6x at year-end (excluding proceeds from the divestiture). Segment highlights: Performance Materials delivered volume-driven growth and remains resilient amid auto market volatility, with full-year PM revenue expected flat to slightly down and EBITDA margins over 50%; Road Technologies posted record North American pavement sales; APT faced continued weak end-market demand and competitive pressure in China — full-year APT revenue is now expected down mid-teens with EBITDA margin of 15–20%. Management narrowed the top end of the company’s full-year sales and EBITDA ranges due to tariff uncertainty and slower industrial demand and scheduled an Investor Update for Dec 8 to present the strategic portfolio review and a 2-year outlook.
